CytomX Therapeutics Inc

NASDAQ:CTMXUnited States

Nov 7, 2024

Show headlines and story abstract

• -- Earnings Flash (CTMX) CYTOMX THERAPEUTICS Posts Q3 Revenue $33.4M, from 4:39PM ET on Thursday Nov 07, 2024 by MT Newswires

  4:39PM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: CTMX
  04:39 PM EST, 11/07/2024 (MT Newswires) -- ...

• CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:10PM ET on Thursday Nov 07, 2024 by Dow Jones

  4:10PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: CTMX
  
  future results; the possibility that CytomX's clinical trials will not be successful; the possibility that current preclinical research may not result in additional product candidates; CytomX's dependence on the success of CX-904, CX-801, and CX-2051; CytomX's reliance on third parties for the manufacture of the Company's product candidates; possible regulatory developments in the United States and foreign countries; and the risk that we may incur higher costs than expected for research and development or unexpected costs and expenses. Additional applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomX's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
  

• *DJ CytomX Therapeutics 3Q EPS 7c >CTMX, from 4:10PM ET on Thursday Nov 07, 2024 by Dow Jones

  4:10PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: CTMX
  
  future results; the possibility that CytomX's clinical trials will not be successful; the possibility that current preclinical research may not result in additional product candidates; CytomX's dependence on the success of CX-904, CX-801, and CX-2051; CytomX's reliance on third parties for the manufacture of the Company's product candidates; possible regulatory developments in the United States and foreign countries; and the risk that we may incur higher costs than expected for research and development or unexpected costs and expenses. Additional applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomX's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.